Compare Immunovant Inc. Common Stock (IMVT) vs MasTec Inc (MTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs MasTec Inc — how do they compare? Immunovant Inc. Common Stock trades at $30.01 (market cap $6.62B), while MasTec Inc trades at $218.15 (market cap $17.94B). The key difference: MasTec Inc is far larger — about 2.7× Immunovant Inc. Common Stock's market cap, and Immunovant Inc. Common Stock is trading nearer its 52-week high, MasTec Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and MasTec Inc for 23 Days on average.
| IMVT | MTZ | |
|---|---|---|
Market Cap | $6.62B | $17.94B |
Volume | 1,131,364 | 1,292,386 |
Sector | Health | Industrials |
52-Week High | $44.96 | $437.51 |
52-Week Low | $17.03 | $190.08 |
Typical Hold Time | 0 Days | 23 Days |
Enterprise Value | $5.72B | $20.86B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MasTec (MTZ) trades at $223.37, down 2.16% today, with technical indicators showing a neutral bias amid mixed moving average signals. The company reported strong Q1 2026 earnings beat but missed Q2 expectations, while maintaining robust revenue growth projections for 2026. Analyst sentiment remains overwhelmingly positive with 88.9% buy ratings and a $408.58 consensus price target representing significant upside potential from current levels.
MTZ's infrastructure expertise positions it well for AI-driven data center and utility investment cycles, though premium valuation metrics and recent cash flow volatility present near-term risks. The stock's investment case hinges on execution of record backlog and margin expansion amid competitive infrastructure markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →
